Wall Street analysts forecast that Merus NV (NASDAQ:MRUS) will post earnings of ($0.71) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Merus’ earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.80). Merus posted earnings per share of ($2.06) in the same quarter last year, which would indicate a positive year over year growth rate of 65.5%. The business is expected to report its next quarterly earnings report on Friday, April 27th.
On average, analysts expect that Merus will report full year earnings of ($4.02) per share for the current financial year, with EPS estimates ranging from ($4.02) to ($4.01). For the next financial year, analysts expect that the company will report earnings of ($3.83) per share, with EPS estimates ranging from ($4.22) to ($3.44). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Merus.
Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Thursday, November 30th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.26). Merus had a negative net margin of 809.20% and a negative return on equity of 119.36%.
A number of research analysts have issued reports on the stock. Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Merus in a report on Thursday, October 26th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $28.00 target price on shares of Merus in a research report on Wednesday, October 18th. Zacks Investment Research raised Merus from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Wedbush reissued an “outperform” rating and set a $32.00 price target on shares of Merus in a report on Friday, January 12th. Finally, BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a report on Saturday, December 30th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $30.25.
Merus (NASDAQ MRUS) traded down $0.27 on Monday, reaching $18.58. 56,100 shares of the company’s stock traded hands, compared to its average volume of 31,457. Merus has a fifty-two week low of $13.23 and a fifty-two week high of $33.63.
TRADEMARK VIOLATION NOTICE: “-$0.71 EPS Expected for Merus NV (MRUS) This Quarter” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/01/0-71-eps-expected-for-merus-nv-mrus-this-quarter.html.
Merus Company Profile
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Get a free copy of the Zacks research report on Merus (MRUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.